Bay Rivers Group Abb Vie Inc. Transaction History

Bay Rivers Group

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 12, 2022	SELL	$137.62 - $174.96 $1.23 Million - $1.56 Million	-8,941 Closed	0 $0
Q1 2022 Apr 20, 2022	SELL	$131.98 - $163.75 $485,422 - $602,272	-3,678 Reduced 29.15%	8,941 $1.45 Million
Q4 2021 Jan 20, 2022	BUY	$107.43 - $135.93 $55,219 - $69,868	514 Added 4.25%	12,619 $1.71 Million
Q3 2021 Oct 13, 2021	BUY	$106.4 - $120.78 $1.29 Million - $1.46 Million	12,105 New	12,105 $1.31 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $317B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Bay Rivers Group, based on Form 13F filings with the SEC.

Stay updated on Bay Rivers Group with notifications on news.